Financial Review: Neumora Therapeutics (NASDAQ:NMRA) and LadRx (OTCMKTS:CYTR)

LadRx (OTCMKTS:CYTR) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Profitability

This table compares LadRx and Neumora Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LadRx	N/A	-67.61%	-45.39%
Neumora Therapeutics	N/A	-73.63%	-68.97%

Earnings & Valuation

This table compares LadRx and Neumora Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LadRx	N/A	N/A	-$6.70 million	($0.15)	N/A
Neumora Therapeutics	N/A	N/A	-$235.93 million	($1.87)	-6.06

Neumora Therapeutics is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

0.1% of LadRx shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 12.8% of LadRx shares are owned by insiders. Comparatively, 26.4% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

LadRx has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 3.34, suggesting that its share price is 234% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for LadRx and Neumora Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LadRx	0	0	0	0	0.00
Neumora Therapeutics	0	1	5	0	2.83

Neumora Therapeutics has a consensus target price of $23.40, indicating a potential upside of 106.53%. Given Neumora Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than LadRx.

Summary

Neumora Therapeutics beats LadRx on 6 of the 11 factors compared between the two stocks.

About LadRx

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

About Neumora Therapeutics

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.